Sangamo Completes Enrollment in Diabetic Neuropathy Trial

Sangamo BioSciences has enrolled all patients in its Phase II trial of SB-509, a potential treatment of mild to moderate diabetic neuropathy. 

 

The 102-patient, randomized, double-blind, repeat-dosing, placebo-controlled, multicenter trial will evaluate SB-509 in patients with diabetic peripheral sensory motor neuropathy in the legs.

Subjects have been randomized to one of two groups. The larger group will receive a 60-mg intramuscular injection of the drug and the other group will receive the same amount of placebo.

Edward Lanphier, Sangamo’s president and CEO, said the company expects to present data from the trial by the end of 2008.